97 related articles for article (PubMed ID: 21154164)
21. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia.
Velardi A; Ruggeri L; Mancusi A; Aversa F; Christiansen FT
Curr Opin Immunol; 2009 Oct; 21(5):525-30. PubMed ID: 19717293
[TBL] [Abstract][Full Text] [Related]
22. Natural killer cell tolerance licensing and other mechanisms.
Jonsson AH; Yokoyama WM
Adv Immunol; 2009; 101():27-79. PubMed ID: 19231592
[TBL] [Abstract][Full Text] [Related]
23. Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells.
Cognet C; Farnarier C; Gauthier L; Frassati C; André P; Magérus-Chatinet A; Anfossi N; Rieux-Laucat F; Vivier E; Schleinitz N
Clin Immunol; 2010 Apr; 135(1):26-32. PubMed ID: 20093094
[TBL] [Abstract][Full Text] [Related]
24. Natural killer cells--new understanding of basic biology may lead to more effective allogeneic haematopoietic stem cell transplantation.
Patil S; Schwarer T
Intern Med J; 2009 Oct; 39(10):639-47. PubMed ID: 19686544
[TBL] [Abstract][Full Text] [Related]
25. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
26. Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission.
Dauguet N; Récher C; Demur C; Fournié JJ; Poupot M; Poupot R
Am J Hematol; 2011 Feb; 86(2):209-13. PubMed ID: 21264910
[TBL] [Abstract][Full Text] [Related]
27. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
28. CD45-mediated regulation of LFA1 function in human natural killer cells. Anti-CD45 monoclonal antibodies inhibit the calcium mobilization induced via LFA1 molecules.
Poggi A; Pardi R; Pella N; Morelli L; Sivori S; Vitale M; Revello V; Moretta A; Moretta L
Eur J Immunol; 1993 Oct; 23(10):2454-63. PubMed ID: 8405045
[TBL] [Abstract][Full Text] [Related]
29. Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors.
Hasenkamp J; Borgerding A; Uhrberg M; Falk C; Chapuy B; Wulf G; Jung W; Trümper L; Glass B
Scand J Immunol; 2008 Mar; 67(3):218-29. PubMed ID: 18226015
[TBL] [Abstract][Full Text] [Related]
30. Microclusters of inhibitory killer immunoglobulin-like receptor signaling at natural killer cell immunological synapses.
Treanor B; Lanigan PM; Kumar S; Dunsby C; Munro I; Auksorius E; Culley FJ; Purbhoo MA; Phillips D; Neil MA; Burshtyn DN; French PM; Davis DM
J Cell Biol; 2006 Jul; 174(1):153-61. PubMed ID: 16801390
[TBL] [Abstract][Full Text] [Related]
31. NK cell receptors as tools in cancer immunotherapy.
Sentman CL; Barber MA; Barber A; Zhang T
Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
[TBL] [Abstract][Full Text] [Related]
32. KIR2DS3 is associated with protection against acute myeloid leukemia.
Shahsavar F; Tajik N; Entezami KZ; Fallah Radjabzadeh M; Asadifar B; Alimoghaddam K; Ostadali Dahaghi M; Jalali A; Ghashghaie A; Ghavamzadeh A
Iran J Immunol; 2010 Mar; 7(1):8-17. PubMed ID: 20371915
[TBL] [Abstract][Full Text] [Related]
33. The low affinity 40,000 Fc gamma receptor and the transferrin receptor can be alternative or simultaneous target structures on cells sensitive for natural killing.
Perl A; Looney RJ; Ryan DH; Abraham GN
J Immunol; 1986 Jun; 136(12):4714-20. PubMed ID: 3011902
[TBL] [Abstract][Full Text] [Related]
34. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.
Alfarra H; Weir J; Grieve S; Reiman T
Front Immunol; 2020; 11():575609. PubMed ID: 33304346
[TBL] [Abstract][Full Text] [Related]
35. Improving the Clinical Application of Natural Killer Cells by Modulating Signals Signal from Target Cells.
Holubova M; Leba M; Gmucova H; Caputo VS; Jindra P; Lysak D
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31311121
[TBL] [Abstract][Full Text] [Related]
36. Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.
Carlsten M; Korde N; Kotecha R; Reger R; Bor S; Kazandjian D; Landgren O; Childs RW
Clin Cancer Res; 2016 Nov; 22(21):5211-5222. PubMed ID: 27307594
[TBL] [Abstract][Full Text] [Related]
37. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.
Vey N; Bourhis JH; Boissel N; Bordessoule D; Prebet T; Charbonnier A; Etienne A; Andre P; Romagne F; Benson D; Dombret H; Olive D
Blood; 2012 Nov; 120(22):4317-23. PubMed ID: 23002117
[TBL] [Abstract][Full Text] [Related]
38. Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?
Felices M; Miller JS
Clin Cancer Res; 2016 Nov; 22(21):5161-5163. PubMed ID: 27430580
[TBL] [Abstract][Full Text] [Related]
39. Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652.
Perez-Santos M; Guerrero-González T; Gómez-Conde E; Cebada J; Flores A; Villa-Ruano N
Expert Opin Ther Pat; 2020 Mar; 30(3):159-162. PubMed ID: 31944149
[No Abstract] [Full Text] [Related]
40. Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma.
Hutchinson AT; Jones DR; Raison RL
Mol Immunol; 2015 Oct; 67(2 Pt A):89-94. PubMed ID: 25964097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
